 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeuroMetrix, Inc. (NASDAQ:NURO  Get Free Report) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 23,200 shares, a decrease of 46.0...

Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Drops By 46.0%

NeuroMetrix, Inc. (NASDAQ:NURO  Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.04 and traded...

NeuroMetrix (NASDAQ:NURO) Share Price Passes Above 200-Day Moving Average of $4.04

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck combined with standard EKG or DPNCheck...

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

NeuroMetrix reports over 2000 patients prescribed Quell Fibromyalgia

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic...

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell  Fibromyalgia

NURO stock price has declined 99% since its IPOGozani has received compensation of over $10 million since the IPOGozani was charged by the FTC for various wrongdoings at NUROGozani apparently...

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholder value- Notes tremendous destruction of shareholder value under company's...

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

NeuroMetrix reports Q4 EPS ($1.43) vs (73c) last year

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The...

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript...

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Volume (M)	163,417.00
52-Wk High	$11.82
52-Wk Low	$2.70

NURO Neurometrix Inc.

About

Feed

News

Earnings

Fundamentals